CIK 0001894562 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · incorporated in DE · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | 4.6 M | 0 | 0 | |
| Net income (USD) | -201.1 M | -198.1 M | -121.8 M | |
| Diluted EPS (USD/shares) | -1.35 | -2.18 | -4.19 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-08-06 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-06 | 8-K | 8-K items 2.02,9.01 | 2026-08-06 |
| 2026-07-08 | 8-K | 8-K items 8.01 | 2026-07-06 |
| 2026-06-08 | 4 | FORM 4 | 2026-06-05 |
| 2026-06-08 | 4 | FORM 4 | 2026-06-05 |
| 2026-06-08 | 4 | FORM 4 | 2026-06-05 |
| 2026-06-08 | 4 | FORM 4 | 2026-06-05 |
| 2026-06-08 | 4 | FORM 4 | 2026-06-05 |
| 2026-06-08 | 4 | FORM 4 | 2026-06-05 |
| 2026-06-08 | 4 | FORM 4 | 2026-06-05 |
| 2026-06-08 | 8-K | 8-K items 5.07 | 2026-06-05 |
| 2026-05-07 | 10-Q | 10-Q | 2026-03-31 |
| 2026-05-07 | 8-K | 8-K items 2.02,9.01 | 2026-05-07 |
| 2026-04-23 | ARS | ARS | 2025-12-31 |
| 2026-04-23 | DEFA14A | DEFA14A | |
| 2026-04-23 | DEF 14A | DEF 14A | 2025-12-31 |
| 2026-04-17 | 4 | FORM 4 | 2026-04-16 |
| 2026-04-17 | 3 | FORM 3 | 2026-04-16 |
| 2026-04-16 | 8-K | 8-K items 5.02 | 2026-04-07 |
| 2026-03-04 | EFFECT | EFFECT items ,, | |
| 2026-03-03 | S-8 | S-8 | |
| 2026-03-03 | POS AM | POS AM | |
| 2026-03-03 | 10-K | 10-K | 2025-12-31 |
| 2026-03-03 | POSASR | POSASR | |
| 2026-03-03 | 8-K | 8-K items 2.02,7.01,9.01 | 2026-03-03 |
Forms on file (last 1,000): 4 118, 8-K 42, 3 20, 10-Q 12, UPLOAD 8, DEFA14A 7, CORRESP 7, DRS/A 7. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=PRME (0.002 USD), /gw/filings/filings?ticker=PRME&form=8-K, /gw/filings/facts?ticker=PRME&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange